Israeli breakthrough migraine treatment erases pain - new study

In a new study published Wednesday in the American Academy of Pain Medicine’s Oxford Journal, breakthrough Israeli technology has been shown to be more effective than standard medication in treating acute migraines in adolescents – widespread migraines those with poor academic performance, reduced school attendance and negative effects on social coexistence and quality of life. Nerivio, a remote electrical neuromodulation (REN) device developed by Theranica, based in Netanya, activates the body’s own conditional pain modulation mechanism to treat headaches and other symptoms related to migraines by stimulating the free nerve endings in the upper arm.A breakthrough Israeli technology has been shown to be more effective than standard drugs (COURTESY) in treating acute migraine headaches in adolescents.Two hours after treatment, 37% of participants with REN achieved freedom from pain compared to 9% of participants who took oral triptans and over-the-counter analgesics, 71% pain relief was achieved with REN versus 57% with medication, and consistency of freedom from pain was achieved with REN 40% versus 9% achieved, consistency of pain relief was achieved 80% with REN versus 57%. In addition, REN has no side effects. In the youth study, only one participant reported a mild device-related side effect – a temporary feeling of pain in the arm that subsided after treatment without intervention. Those who take triptans often report drowsiness, fatigue, and difficulty concentrating for up to 24 hours after taking a pill.

cnxps.cmd.push (function () {cnxps ({playerId: ’36af7c51-0caf-4741-9824-2c941fc6c17b’}). render (‘4c4d856e0e6f4e3d808bbc1715e132f6’);});

if (window.location.pathname.indexOf (“656089”)! = -1) {console.log (“hedva connatix”); document.getElementsByClassName (“divConnatix”)[0].style.display = “none”;} 35 young people took part in the study and were treated in two phases. In the run-in phase, migraine attacks were treated with medication. In the intervention phase, they were treated with REN. An additional, large-scale, blinded, comparative efficacy and tolerability study would be required to confirm the results. However, previous studies showed similar effectiveness in adults. The device is approved in the United States by the Food and Drug Administration and approved by the Israel Ministry of Health, where it is available through the local health fund. Nerivio has treated more than 100,000 migraines in over 14,000 patients, the company said; it treats about 100 patients in Israel every month. It was developed with the research and guidance of Professor David Yarnitsky, director of the Department of Neurology at Technion – the Israel Institute of Technology. The company’s CEO, Alon Ironi, a trained electronics technician, decided to develop the device when his daughter was suffering from migraines. Migraines are one of the most common and debilitating diseases in the world. The headaches often make those who cause them incapacitated, which has a negative impact on the economy. “Migraine is the third most common disease in the world, affecting approximately 1 billion people,” said James Johnson, chief executive of MedTech Breakthrough. Nerivio was named “Best New Technology Solution” in the Pain Management category at the MedTech Breakthrough Awards in May. There were around 3,850 nominations from 17 countries for the award. Ironi led The Jerusalem Post through standard treatment, stating that users turn on the device when a seizure sets in – either for headache or other related migraine symptoms such as poor eyesight, nausea, hypersensitivity to sound, Light or smell. Patients place the device on their upper arms and begin the treatment, which should last 45 minutes, but it can also take less. “During treatment, patients can go about their normal activities,” said Ironi. “The only two things they can’t do is swim or shower because it’s an electronic device.” After the session, patients simply put the device back in the box and keep it for the next attack. Nerivio comes with an application that makes the treatment more personalized, he said. An interactive migraine diary records treatment sessions and symptoms that can then be shared with the doctor. The device also gives recommendations on how to optimize treatments for better personal results. “There’s nothing like it in the migraine market,” said Dr. Shira Markowitz, an independent general neurologist and head and facial pain specialist at Shaare Zedek Medical Center and Maccabi Health Services. She told the Post that “the fascinating thing about it is that it doesn’t stimulate the nerves around the skull that are commonly believed to be involved in migraines.” “It’s more like something hurts and we hit a different spot and then our body forgets about the other pains or releases chemicals that cause pain relief.” Migraines at arm’s length. “